Lumenis Expands Its Portfolio of Gynecology Solutions With the New UltraPulse(R) DUO(TM) for Fertility-Related Disorders and FemTouch(TM) for Improved Vaginal Health

LAS VEGAS, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced today that the company will showcase its new UltraPulse DUO CO2 laser system and the new FemTouch solution at the American Association of Gynecologic Laparoscopists (AAGL) Annual Meeting, taking place November 15-19, 2015 in Las Vegas, Nevada.

UltraPulse DUO is the newest addition to the Lumenis CO2 laser family, and provides gynecologists and fertility experts with an ultra-precise CO2 laser solution for the treatment of selected fertility related indications. The unique energy delivery is based on high level of control over each single pulse, which leads to uncompromised precision, and translates to excellent clinical outcomes.

"Treating endometriosis lesions on critical intra-abdominal structures such as the bowel, bladder, ureter and major blood vessels is utterly challenging as one needs to avoid perforations, minimize risk of adhesion formation and other potential complications," said Ceana Nezhat, MD, FACOG, FACS, Atlanta, Georgia. "Using CO2 laser fibers during laparoscopic procedures enables us to precisely target the desired treatment areas with markedly reduced thermal damage to surrounding tissues; it is the wave of the future in minimally invasive gynecological surgery."

UltraPulse DUO is an innovative computer-controlled, user-friendly CO2 laser platform, which provides high energy transmission for reproducible laser-tissue interaction. The system is designed to deliver the CO₂ laser energy via an articulated arm or through a Lumenis laser fiber. The advanced fiber used either in robotic surgery or with specially designed gynecology laparoscopic handpieces, is durable, flexible and with a renewable tip. In addition, the aiming beam helps assure accurate positioning and targeting of the desired tissue with excellent visualization of the surgical plane.

In addition to the advanced UltraPulse DUO system, Lumenis expands its laser solutions to vaginal health conditions, with the launch of FemTouch. FemTouch was developed in collaboration with leading gynecologists and addresses vaginal health conditions by promoting the remodeling of the vaginal wall. The treatment with FemTouch can be performed as an office procedure; it is fast, simple and does not require anesthesia and virtually no post-procedural care. Preliminary reports from patients and physicians indicate that the treatment is associated with very minimal discomfort for patients, and that women being treated with FemTouch reported improvement in their condition after one to two procedures. FemTouch is offered as an add-on to Lumenis' AcuPulse™ product family.

"FemTouch is an effective, safe and fast treatment for women who want to improve their vaginal health," said Dr. Massimiliano Marziali, Paideia Clinic, Rome, Italy. "I am excited to add this treatment to my practice as the patients I have treated so far are satisfied with the clinical outcomes and with the overall procedure which takes only a few minutes and is generally comfortable to them. I believe that FemTouch is the future of vaginal health as its simplicity of usage leads to better clinical outcomes and the product can be effective for additional gynecological indications."

"We are very excited with the introduction of our two new solutions for the dynamic and developing market of gynecological procedures," said Tzipi Ozer-Armon, CEO of Lumenis. "With our commitment to providing women with the best treatment options for their gynecological health, we collaborated with leading physicians to develop these comprehensive solutions to elevate the gynecological care for women."

To learn more about the UltraPulse DUO and the FemTouch please visit the Lumenis booth #443.

Additionally, Lumenis invites you to join their breakfast symposium - "A New Day for CO2 Laser Laparoscopic Surgery for Endometriosis" with Dr. Ceana Nezhat, Dr. David Olive and Dr. Francisco Carmona. They will present and showcase their expertise with the Lumenis CO2 lasers for delicate endometriosis procedures and fertility preservation.

The symposium will be held on Tuesday, November 18th, 6:00- 7:45am at the MGM Grand Hotel Las Vegas, Room # 309.

About Lumenis

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com

PM360 embraces diversity, gender equality, ideas, and innovation that advance bold ideas in pharmaceutical marketing. PM360 is the premier magazine for marketing decision makers in the pharmaceutical, biotech, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharma marketing professionals to succeed in the complex healthcare environment.